Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phenylpropanolamine increases plasma caffeine levels.

C R Lake1, D B Rosenberg, S Gallant

  • 1Department of Psychiatry, F. Edward Hebert School of Medicine, Uniformed Services University, Bethesda.

Clinical Pharmacology and Therapeutics
|June 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of chronic prenatal MK-801 treatment on object recognition, cognitive flexibility, and drug-induced locomotor activity in juvenile and adult rat offspring.

Behavioural brain research·2017
Same author

Luer lock drain bottles. A simple and practical device for fat harvesting.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2010
Same author

Effect of carnosine on Drosophila melanogaster lifespan.

Bulletin of experimental biology and medicine·2002
Same author

Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir.

Therapeutic drug monitoring·2001
Same author

Assessment of the COOP charts with and without pictures in a Swiss population.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2000
Same author

Carnosine as a potential anti-senescence drug.

Biochemistry. Biokhimiia·2000
Same journal

Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2/MATE-Mediated Renal Drug-Drug Interactions in Healthy Volunteers.

Clinical pharmacology and therapeutics·2026
Same journal

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

Clinical pharmacology and therapeutics·2026
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
Same journal

Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

Clinical pharmacology and therapeutics·2026
Same journal

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

Clinical pharmacology and therapeutics·2026
Same journal

Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

Clinical pharmacology and therapeutics·2026
See all related articles

Phenylpropanolamine significantly increases caffeine levels in the body, potentially leading to more side effects. This drug interaction may explain reported adverse reactions when caffeine and phenylpropanolamine are consumed together.

Area of Science:

  • Pharmacology
  • Toxicology

Background:

  • Caffeine and phenylpropanolamine activate the central and sympathetic nervous systems.
  • Combined use has been linked to severe hypertensive reactions, sometimes fatal.

Purpose of the Study:

  • To investigate the pharmacokinetic interaction between phenylpropanolamine and caffeine.
  • To understand how these commonly used substances affect each other in the body.

Main Methods:

  • Sixteen healthy subjects participated in the study.
  • Participants received combinations of caffeine, phenylpropanolamine, and placebo.
  • Plasma concentrations and physical side effects were monitored.

Main Results:

  • Peak plasma caffeine concentrations were significantly higher (8.0 ± 2.2 µg/ml) when combined with phenylpropanolamine compared to caffeine alone (2.1 ± 0.3 µg/ml).

Related Experiment Videos

  • Physical side effects and increases in both systolic and diastolic blood pressure were more pronounced with the combination.
  • Phenylpropanolamine may enhance caffeine absorption or inhibit its elimination.

    • Conclusions:

    • Phenylpropanolamine significantly alters caffeine pharmacokinetics.
    • This interaction can lead to increased caffeine levels and adverse effects, explaining reported side effects from combined use.